News and journals

Get the latest updates on preclinical research. Access our scientific publications, company milestones, and industry events. Discover how Sus Clinicals is transforming development of breakthrough therapeutics to fight diseases faster.

Press releases

Publications

Oncopig bladder cancer cells recapitulate human bladder cancer treatment responses in vitro

The published work (Segatto et al. 2024 Front. Oncol., 25 February 2024) discusses the development of a novel urothelial carcinoma cell line from Oncopigs®, Sus Clinicals’ genetically modified porcine model. The aim was to create a reliable in vitro model for bladder cancer research. The researchers successfully demonstrated that these Oncopig® bladder cancer cell lines mimic human bladder cancer cell responses to commonly used chemotherapeutic agents (cisplatin, doxorubicin, and gemcitabine).

Effect of CRISPR Knockout of AXIN1 or ARID1A on Proliferation and Migration of Porcine Hepatocellular Carcinoma

In a groundbreaking study, scientists have used advanced genetic editing techniques (CRISPR) to create customized porcine models for studying liver cancer, specifically hepatocellular carcinoma (HCC). The researchers focused on two key genes, AXIN1 and ARID1A, which are frequently mutated in human liver cancer, and successfully replicated these mutations in pigs. This work lays the foundation for development and utilization of genetically-tailored porcine HCC models for in vivo testing of novel therapeutic approaches in a clinically-relevant large animal model.

Porcine Cancer Models: Potential Tools to Enhance Cancer Drug Trials

The amount of time and money invested into cancer drug research, development, and clinical trials has continually increased over the past few decades. Despite record high cancer drug approval rates, cancer remains a leading cause of death. This suggests the need for more effective tools to help bring novel therapies to clinical practice in a timely manner.

Translating Human Cancer Sequences Into Personalized Porcine Cancer Models

The global incidence of cancer is rapidly rising, and despite an improved understanding of cancer molecular biology, immune landscapes, and advancements in cytotoxic, biologic, and immunologic anti-cancer therapeutics, cancer remains a leading cause of death worldwide. The authors explain that by creating pig models that mirror patients' genetic profiles, researchers can improve the predictability of treatment outcomes and accelerate progress in cancer research and treatment.

Of Mice, Dogs, Pigs, and Men: Choosing the Appropriate Model for Immuno-Oncology Research

Cancer has recently surpassed cardiovascular diseases as the leading cause of death worldwide. The increasing cancer incidence combined with the emergence of improved therapeutic strategies has driven research into fields such as how the immune system Influences cancer development and progression. This article reviews various animal models, and explains the benefits of porcine-based preclinical research.

KRASG12D And TP53R167H Cooperate to Induce Pancreatic Ductal Adenocarcinoma in Sus Scrofa Pigs

This article details development of the first large animal model of pancreatic carcinogenesis and may allow for insight into new avenues of translational research not before possible in rodents. By developing a porcine model via the Oncopig platform that closely mimics human pancreatic ductal adenocarcinoma (PDAC), researchers can now explore new treatment modalities, surgical interventions, and radiological techniques that were previously unfeasible in mouse models.

The Oncopig Cancer Model as a Complementary Tool for Phenotypic Drug Discovery

The screening of potential therapeutic compounds using phenotypic drug discovery (PDD) is being embraced once again by researchers and pharmaceutical companies as an approach to enhance the development of new effective therapeutics. Before the genomics and molecular biology era and the consecutive emergence of targeted-drug discovery approaches, PDD was the most common platform used for drug discovery. This article covers how a transgenic pig model can offer a controlled and predictable platform for studying cancer and testing new therapies.

The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform

Cancer is a global epidemic causing more than 8 million annual deaths worldwide. The more than 13 million new cancer diagnoses made each year carry an economic burden of $290B. Cancer is expected to be the second leading cause of death in the United States in 2017. The authors discuss how the Oncopig Cancer Model represents a significant breakthrough in cancer research, providing a powerful and clinically relevant tool to study cancer biology, test therapeutic interventions, and improve patient outcomes in the fight against cancer.

A Validated, Transitional and Translational Porcine Model of Hepatocellular Carcinoma

This article details a study validating the Oncopig model for hepatocellular carcinoma (HCC). Specifically, the article presents data demonstrating the ability of Oncopig HCC cell lines to recapitulate key features of human HCC, providing validation for the use of the Oncopig platform for human HCC research. This model will enable the testing of different HCC treatment techniques and the evaluation of histologic, radiographic, and pathological responses in a model more similar to human HCC than currently available small animal models.

Oncopig Soft-Tissue Sarcomas Recapitulate Key Transcriptional Features of Human Sarcomas

Human soft-tissue sarcomas (STS) are rare mesenchymal tumors with a 5-year survival rate of 50%, highlighting the need for further STS research. Research has been hampered by limited human sarcoma cell line availability and the large number of STS subtypes, making development of STS cell lines and animal models representative of the diverse human STS subtypes critical. Pigs represent ideal human disease models due to their similar size, anatomy, metabolism, and genetics compared to humans.

Featured event

Check back soon for more information about our next featured event.

See all events

Press releases

Sus Clinicals Appoints Dr. Lawrence Schook to Board of Directors

Sus Clinicals, Inc. announced today that Dr. Lawrence Schook has been elected to the Company’s Board of Directors

Sus Clinicals, Inc. Announces $2 Million Research Grant from the National Institutes of Health

Funding will support breakthrough work against an aggressive form of liver cancer

Sus Clinicals, Inc. Announces Former Jackson Labs Executive Joins the Company as Advisor

Dr. Auro Nair brings over three decades of experience in life sciences and biomedical research

Sus Clinicals, Inc. Announces Formation of Advisory Council

Top experts to advise Company on scientific priorities and innovation strategies

Sus Clinicals Announces Former McKinsey Executive Joins the Company as Advisor

Jeff Sinclair brings 30+ years of experience in strategy, operations and organization design

Sus Clinicals, Inc. Receives Clearance from the U.S. Food & Drug Administration

Grant of Enforcement Discretion Supports Commercial Launch

Sus Clinicals, Inc. Announces New License Agreement for Advancement in Cancer-Related Research

Patent-Pending Technology from the University of Illinois Leverages Large Animal Model to Accelerate Pre-Clinical Testing for Cancer Therapies

Subscribe to our newsletter

Stay connected

Linkedin Youtube X-twitter Facebook Envelope

Sus Clinicals Welcomes New CEO

Effective August 1, 2024, Jessicca M. Rege, Ph.D. joins Sus Clinicals as CEO.

Dr. Rege brings deep scientific expertise and a demonstrated track record of cross-functional business and scientific leadership, from start-ups to major global pharmaceutical players.

“I am thrilled to be joining the Sus Clinicals team,” said Dr. Rege. “My passion is to accelerate transformative research and therapeutics into the clinic, with the hope to save lives.  To bring the qualified and FDA cleared Oncopig® platform to more researchers is a wonderful opportunity professionally and for the patients we all serve.”

Most recently Dr. Rege was Chief Development Officer of Mural Oncology. Prior to Mural she served as VP, Head of Clinical Development, Oncology at Alkermes. Over her career she has held multiple leadership roles in larger pharmaceuticals companies, all with significant oncology portfolios, including Daiichi-Sankyo, Eli Lilly and Eisai Inc., to name a few.

“Dr. Rege’s educational background, her extensive pharmaceuticals experience, and her superb leadership skills all position her well to take Sus Clinicals to the next level,” said Jeff Weedman, Board Chair and Co-Founder of the Company.

click Me

Products and Services
News and Journals
About Us